VivoSim Labs, Inc. (VIVS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VIVS SEC filings page.
VivoSim Labs, Inc. (VIVS) reported $112K in revenue over the twelve months to Jun 30, 2026, down 21.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business remains development-stage: research and overhead spending vastly exceed a tiny revenue base, creating recurring cash outflows.
In FY2025, operating cash outflow exceeded the reported net loss by roughly$7.0M ; in FY2026, the gap narrowed to about$3.0M . Cash conversion therefore moved closer to the accounting result, indicating that the later loss was less separated from actual cash use.
FY2026 revenue was only
FY2026 financing provided
Financial Health Signals
VivoSim Labs, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
VivoSim Labs, Inc. scores -71.82, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.1M) relative to total liabilities ($8.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
VivoSim Labs, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
VivoSim Labs, Inc. reported a net loss of $13.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
VivoSim Labs, Inc. reported an operating loss of $11.5M against $12K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
VivoSim Labs, Inc. generated $18K in revenue in Q1 2027. This represents a decrease of 51.4% from the same quarter a year earlier. Against the prior quarter it is down 55.0%.
VivoSim Labs, Inc.'s EBITDA was -$2.7M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.7% from the same quarter a year earlier. Against the prior quarter it is up 13.5%.
VivoSim Labs, Inc. reported -$1.3M in net income in Q1 2027. This represents an increase of 52.9% from the same quarter a year earlier. Against the prior quarter it is up 76.8%.
Cash & Balance Sheet
VivoSim Labs, Inc. recorded an outflow of $3.2M in free cash flow in Q1 2027, representing a cash shortfall after capex. This represents an increase of 17.9% from the same quarter a year earlier. Against the prior quarter it is down 44.6%.
VivoSim Labs, Inc. held $1.7M in cash as of Q1 2027; long-term debt is not reported for that period.
Not reported for Q1 2027.
Margins & Returns
Not reported for Q1 2027.
Not shown for Q1 2027: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q1 2027: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q1 2027.
Capital Allocation
VivoSim Labs, Inc. invested $1.1M in research and development in Q1 2027. This represents an increase of 13.1% from the same quarter a year earlier. Against the prior quarter it is up 0.6%.
VivoSim Labs, Inc. invested $23K in capex in Q1 2027, funding long-term assets and infrastructure.
Not reported for Q1 2027.
VIVS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18K-51.4% | $40K-21.6% | $26K+8.3% | $28K-6.7% | $37K-5.1% | $51K | $24K+380.0% | $30K |
| Cost of Revenue | N/A | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0 | $2K | $1K |
| Gross Profit | N/A | $40K-21.6% | $26K+18.2% | $28K-3.4% | $37K0.0% | $51K | $22K+340.0% | $29K |
| R&D Expenses | $1.1M+13.1% | $1.1M+31.0% | $1.1M-36.0% | $923K-6.2% | $1.0M-28.6% | $859K | $1.8M+24.1% | $984K-26.3% |
| SG&A Expenses | $1.6M-15.7% | $2.1M-10.4% | $1.6M-4.3% | $1.7M+5.3% | $2.0M-3.5% | $2.3M | $1.7M-24.0% | $1.7M-40.5% |
| Operating Income | -$2.8M+5.4% | -$3.2M-1.0% | -$2.8M+20.7% | -$2.6M-1.0% | -$2.9M+13.9% | -$3.2M | -$3.5M+5.8% | -$2.6M+36.6% |
| EBITDA | -$2.7M+4.7% | -$3.1M-1.6% | -$2.7M+20.7% | -$2.6M-1.4% | -$2.9M+13.9% | -$3.1M | -$3.4M+5.8% | -$2.5M+37.2% |
| Interest Expense | $4K0.0% | $4K-20.0% | $4K-20.0% | $0 | $4K | $5K | $5K | $0 |
| Income Tax | $3K | $0 | $0 | $2K | $0-100.0% | $0 | $0 | $0 |
| Net Income | -$1.3M+52.9% | -$5.8M-184.1% | -$2.7M+21.9% | -$2.5M+0.2% | -$2.8M+15.0% | $6.9M | -$3.4M+4.4% | -$2.5M+36.2% |
| EPS (Basic) | -$0.25+78.1% | -$2.21-92.2% | -$1.03+54.8% | -$0.98+41.7% | -$1.14+58.4% | -$1.15+93.6% | -$2.28-470.0% | -$1.68-265.2% |
| EPS (Diluted) | -$0.25 | -$2.21-92.2% | -$1.03 | -$0.98 | -$1.14 | -$1.15 | -$2.28 | -$1.68 |
| Diluted Shares (Avg) | 5M | N/A | 3M | 3M | 3M | N/A | 2M | 1M |
VIVS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.8M-67.9% | $7.4M-49.6% | $7.0M+81.1% | $9.7M+43.4% | $12.0M+26.5% | $14.7M+130.7% | $3.8M-56.7% | $6.8M-39.5% |
| Current Assets | $3.2M-66.7% | $6.6M-45.4% | $6.0M+187.7% | $7.6M+58.7% | $9.7M+32.9% | $12.1M+208.2% | $2.1M-66.4% | $4.8M-42.3% |
| Cash & Equivalents | $1.7M-81.6% | $5.0M-55.6% | $4.3M+269.3% | $6.7M+110.4% | $9.1M+46.4% | $11.3M+289.9% | $1.2M-78.1% | $3.2M-58.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $0 | $640K |
| Accounts Receivable | $29K-9.4% | $32K+6.7% | $33K+26.9% | $32K+10.3% | $32K-33.3% | $30K-9.1% | $26K-21.2% | $29K-47.3% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $6.2M+153.8% | $8.5M+104.1% | $2.5M-27.6% | $2.6M-14.7% | $2.4M-13.1% | $4.2M+51.3% | $3.5M+28.9% | $3.1M+13.6% |
| Current Liabilities | $1.9M-11.6% | $2.8M-25.5% | $2.5M-15.7% | $2.4M+1.4% | $2.1M+5.4% | $3.7M+100.9% | $2.9M+72.8% | $2.4M+50.9% |
| Non-Current Liabilities | $4.3M+1343.0% | $5.7M+1253.9% | $44K-91.9% | $172K-73.9% | $298K-61.5% | $421K-52.6% | $543K-45.6% | $660K-40.3% |
| Total Equity | -$2.3M-124.6% | -$1.1M-110.5% | $4.4M+1120.1% | $7.1M+92.0% | $9.5M+43.2% | $10.5M+191.4% | $364K-94.1% | $3.7M-56.5% |
| Retained Earnings | -$357.3M-3.6% | -$356.0M-4.0% | -$350.2M-0.4% | -$347.5M-0.6% | -$345.0M-0.6% | -$342.2M-0.7% | -$349.0M-3.7% | -$345.6M-3.8% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
VIVS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M+18.5% | -$2.2M-10.0% | -$2.3M-26.1% | -$2.4M+10.0% | -$3.9M-32.1% | -$2.0M+23.8% | -$1.8M+48.9% | -$2.6M+16.1% |
| Depreciation & Amortization | $40K-34.4% | $43K-29.5% | $52K-22.4% | $59K-13.2% | $61K-12.9% | $61K-14.1% | $67K-5.6% | $68K-4.2% |
| Stock-Based Compensation | $91K+16.7% | N/A | $67K-48.5% | $72K-53.5% | $78K-50.0% | N/A | $130K-17.2% | $155K-77.0% |
| Capital Expenditures | $23K | $0 | $0 | $0-100.0% | $0 | $0 | $0 | $13K-51.9% |
| Free Cash Flow | -$3.2M+17.9% | -$2.2M-10.0% | -$2.3M-26.1% | -$2.4M+10.4% | -$3.9M-32.1% | -$2.0M+23.8% | -$1.8M+48.9% | -$2.7M+16.4% |
| Investing Cash Flow | -$23K | $94K-99.0% | $0-100.0% | $0 | $0-100.0% | $9.0M+69138.5% | $4K-85.2% | $0-100.0% |
| Financing Cash Flow | -$118K-107.0% | $2.9M-9.6% | -$118K+45.4% | $0+100.0% | $1.7M-73.1% | $3.2M+1106.4% | -$216K-118.4% | -$371K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VIVS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 100.0%0.0pp | 100.0%+8.3pp | 100.0%+3.3pp | 100.0%+5.1pp | 100.0% | 91.7%-8.3pp | 96.7% |
| Operating Margin | -15327.8% | -7967.5% | -10576.9% | -9410.7% | -7878.4% | -6184.3% | -14450.0% | -8693.3% |
| Net Margin | -7433.3% | -14410.0% | -10350.0% | -9089.3% | -7683.8% | 13435.3% | -14362.5% | -8496.7% |
| Return on Equity | N/A | N/A | -60.6%+886.4pp | -36.0%+33.2pp | -29.8%+20.4pp | 65.3% | -947.0%-888.7pp | -69.3%-22.0pp |
| Return on Assets | -34.8%-11.0pp | -78.0%-124.8pp | -38.7%+51.0pp | -26.3%+11.5pp | -23.7%+11.6pp | 46.8% | -89.7%-49.1pp | -37.7%-2.0pp |
| Current Ratio | 1.70-2.8x | 2.38-0.9x | 2.44+1.7x | 3.10+1.1x | 4.52+0.9x | 3.25+1.1x | 0.71-3.0x | 1.98-3.2x |
| Debt-to-Equity | N/A | N/A | 0.57-9.0x | 0.37-0.5x | 0.26-0.2x | 0.40-0.4x | 9.56+9.1x | 0.84+0.5x |
| Asset Turnover | 0.000.0x | 0.010.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00 | 0.010.0x | 0.000.0x |
| FCF Margin | -17977.8% | -5595.0% | -8734.6% | -8492.9% | -10648.7% | -3990.2% | -7504.2% | -8850.0% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$1.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| VivoSim Labs, Inc. VIVS | FY2026 | $131K | -$13.8M | N/A | $2.1M | — |
| Matinas BioPharma Holdings, Inc. MTNB | FY2025 | N/A | -$10.3M | N/A | $2.3M | — |
| ESSA Pharma Inc. EPIX | FY2024 | N/A | -$28.5M | N/A | $9.5M | — |
| Processa Pharmaceuticals, Inc. PCSA | FY2025 | N/A | -$13.6M | N/A | $4.7M | — |
| Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock CYCCP | FY2025 | $747K | $3.0M | N/A | $9.6M | — |
Where VivoSim Labs, Inc. Ranks
Frequently Asked Questions
What is VivoSim Labs, Inc.'s annual revenue?
VivoSim Labs, Inc. (VIVS) reported $131K in total revenue for fiscal year 2026. This represents a -9.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is VivoSim Labs, Inc.'s revenue growing?
VivoSim Labs, Inc. (VIVS) revenue declined by 9.0% year-over-year, from $144K to $131K in fiscal year 2026.
Is VivoSim Labs, Inc. profitable?
No, VivoSim Labs, Inc. (VIVS) reported a net income of -$13.8M in fiscal year 2026.
What is VivoSim Labs, Inc.'s EBITDA?
VivoSim Labs, Inc. (VIVS) had EBITDA of -$11.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is VivoSim Labs, Inc.'s gross margin?
VivoSim Labs, Inc. (VIVS) had a gross margin of 100.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is VivoSim Labs, Inc.'s free cash flow?
VivoSim Labs, Inc. (VIVS) recorded an outflow of $10.8M in free cash flow during fiscal year 2026. This represents a -14.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is VivoSim Labs, Inc.'s operating cash flow?
VivoSim Labs, Inc. (VIVS) recorded an outflow of $10.8M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are VivoSim Labs, Inc.'s total assets?
VivoSim Labs, Inc. (VIVS) had $7.4M in total assets as of fiscal year 2026, including both current and long-term assets.
What are VivoSim Labs, Inc.'s capital expenditures?
VivoSim Labs, Inc. (VIVS) reported no capital expenditure during fiscal year 2026.
How much does VivoSim Labs, Inc. spend on research and development?
VivoSim Labs, Inc. (VIVS) invested $4.2M in research and development during fiscal year 2026.
What is VivoSim Labs, Inc.'s current ratio?
VivoSim Labs, Inc. (VIVS) had a current ratio of 2.38 as of fiscal year 2026, which is generally considered healthy.
What is VivoSim Labs, Inc.'s return on assets (ROA)?
VivoSim Labs, Inc. (VIVS) had a return on assets of -187.4% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is VivoSim Labs, Inc.'s P/E ratio?
VivoSim Labs, Inc. (VIVS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.1M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is VivoSim Labs, Inc.'s price-to-sales ratio?
VivoSim Labs, Inc. (VIVS) trades at 18.8x sales, its market capitalization divided by revenue of $112K revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.1M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does VivoSim Labs, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, VivoSim Labs, Inc. (VIVS) held $5.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.8M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is VivoSim Labs, Inc.'s debt-to-equity ratio negative or not reported?
VivoSim Labs, Inc. (VIVS) has negative shareholder equity of -$1.1M as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is VivoSim Labs, Inc.'s Altman Z-Score?
VivoSim Labs, Inc. (VIVS) has an Altman Z-Score of -71.82, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is VivoSim Labs, Inc.'s Piotroski F-Score?
VivoSim Labs, Inc. (VIVS) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are VivoSim Labs, Inc.'s earnings high quality?
VivoSim Labs, Inc. (VIVS) reported a net loss of $13.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can VivoSim Labs, Inc. cover its interest payments?
VivoSim Labs, Inc. (VIVS) reported an operating loss of $11.5M against $12K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.